Daiichi Sankyo Company, Limited (TYO:4568)
Japan
· Delayed Price · Currency is JPY 3,571.00
-14.00 (-0.39%)
Aug 14, 2025, 3:30 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
97.38M JPY
Profits / Employee
14.97M JPY
Market Cap
6,609.71B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 13,643 |
| Shionogi & | 4,955 |
| Olympus | 29,297 |
| M3, Inc. | 15,360 |
Daiichi Sankyo Company News
- 4 hours ago - Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC - Business Wire
- 13 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Daiichi Sankyo has inventory buffer, will expand production capacity in Ohio to mitigate US tariffs - CFO - CNBC
- 14 days ago - Daiichi Sankyo reports Q1 results - Seeking Alpha
- 4 weeks ago - AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
- 4 weeks ago - ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 7 weeks ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 7 weeks ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga